Adenovirus-mediated delivery of interferon-γ gene inhibits the growth of nasopharyngeal carcinoma

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Liu, Ran yi ^a   Zhu, Ying hui ^a   Zhou, Ling ^a   Zhao, Peng ^a,b   Li, Hong li ^a,c   Zhu, Lan cai ^a   Han, Hong yu ^a   Lin, Huan xin ^a   Kang, Liang ^d   Wu, Jiang xue ^a   Huang, Wenlin ^a,e,f  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e INSTITUTE OF MICROBIOLOGY   (China)

^f Science Park   (China)

Author keywords

Adenoviral vector; Gene therapy; Interferon ; Nasopharyngeal carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; GAMMA INTERFERON; HOE 33342; LIPOCORTIN 5; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING ASSAY; BLOOD CULTURE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE CULTURE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL PROLIFERATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INTERFERON-GAMMA; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873968107     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-256     Document Type: Article

References (48)

1. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 2012, 31:185-196.
2. Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009, 74:1070-1076. 10.1016/j.ijrobp.2008.09.008, 19231110.
3. Pan XB, Zhu XD. Role of chemotherapy in stage IIb nasopharyngeal carcinoma. Chin J Cancer 2012, 31:573-578.
4. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795. 10.1146/annurev.immunol.15.1.749, 9143706.
5. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75:163-189.
6. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 2000, 60:3904-3908.
7. Sasagawa T, Hlaing M, Akaike T. Synergistic induction of apoptosis in murine hepatoma Hepa1-6 cells by IFN-gamma and TNF-alpha. Biochem Biophys Res Commun 2000, 272:674-680. 10.1006/bbrc.2000.2835, 10860813.
8. Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 2001, 49:251-262. 10.1136/gut.49.2.251, 1728385, 11454803.
9. Wu J, Xiao X, Zhao P, Xue G, Zhu Y, Zhu X, Zheng L, Zeng Y, Huang W. Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res 2006, 12:4702-4713. 10.1158/1078-0432.CCR-06-0520, 16899621.
10. Zhao P, Zhu YH, Wu JX, Liu RY, Zhu XY, Xiao X, Li HL, Huang BJ, Xie FJ, Chen JM, et al. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth. Life Sci 2007, 81:695-701. 10.1016/j.lfs.2007.05.028, 17714738.
11. Kane A, Yang I. Interferon-gamma in brain tumor immunotherapy. Neurosurg Clin N Am 2010, 21:77-86. 10.1016/j.nec.2009.08.011, 19944968.
12. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000, 82:1138-1144. 2363351, 10735496.
13. Hastie C. Interferon gamma, a possible therapeutic approach for late-stage prostate cancer?. Anticancer Res 2008, 28:2843-2849.
14. Miller CH, Maher SG, Young HA. Clinical use of Interferon-gamma. Ann N Y Acad Sci 2009, 1182:69-79. 10.1111/j.1749-6632.2009.05069.x, 20074276.
15. Dummer R, Eichmuller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther 2010, 18:1244-1247. 10.1038/mt.2010.52, 2889748, 20372104.
16. Wu J, Xiao X, Jia H, Chen J, Zhu Y, Zhao P, Lin H, Huang W. Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. BMC Cancer 2009, 9:55. 10.1186/1471-2407-9-55, 2667533, 19216804.
17. Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK, et al. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene 2011, 30:4814-4823. 10.1038/onc.2011.189, 3165083, 21625209.
18. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285. 10.1016/S0092-8674(00)81848-6, 9008168.
19. Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH, Zeng YX, Huang W. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer 2006, 118:2064-2071. 10.1002/ijc.21585, 16287067.
20. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002, 13:95-109. 10.1016/S1359-6101(01)00038-7, 11900986.
21. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD. Interferon-gamma and cancer immunoediting. Immunol Res 2005, 32:231-245. 10.1385/IR:32:1-3:231, 16106075.
22. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 2005, 65:2906-2913. 10.1158/0008-5472.CAN-04-4282, 15805293.
23. Gattacceca F, Pilatte Y, Billard C, Monnet I, Moritz S, Le Carrou J, Eloit M, Jaurand MC. Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res 2002, 8:3298-3304.
24. Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004, 104:1631-1638. 10.1182/blood-2004-01-0360, 15161670.
25. Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front Biosci 2000, 5:D479-D487. 10.2741/Sangfelt, 10762599.
26. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8:237-249. 10.1023/A:1023668705040, 12766484.
27. Gollob JA, Sciambi CJ, Huang Z, Dressman HK. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res 2005, 65:8869-8877. 10.1158/0008-5472.CAN-05-1387, 16204058.
28. Wall L, Burke F, Barton C, Smyth J, Balkwill F. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 2003, 9:2487-2496.
29. Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 2005, 65:3447-3453.
30. Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res 2011, 17:6118-6124. 10.1158/1078-0432.CCR-11-0482, 3186825, 21705455.
31. Ruiz-Ruiz C, de Almodovar Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A. The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem 2004, 279:19712-19720. 10.1074/jbc.M313023200, 14993214.
32. Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H, Dong M, Hyodoh F, Yata K, Wada H, et al. TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res 2006, 26:4115-4124.
33. Barton C, Davies D, Balkwill F, Burke F. Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer 2005, 41:1474-1486. 10.1016/j.ejca.2005.03.022, 15949937.
34. Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A. IP-10 induces dissociation of newly formed blood vessels. J Cell Sci 2009, 122:2064-2077. 10.1242/jcs.048793, 2723158, 19470579.
35. Bodnar RJ, Yates CC, Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res 2006, 98:617-625. 10.1161/01.RES.0000209968.66606.10, 16484616.
36. Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer 2002, 86:768-773. 10.1038/sj.bjc.6600152, 2375312, 11875741.
37. Lu Y, Yang W, Qin C, Zhang L, Deng J, Liu S, Qin Z. Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol 2009, 183:6413-6421. 10.4049/jimmunol.0901073, 19841170.
38. Kommineni VK, Nagineni CN, William A, Detrick B, Hooks JJ. IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun 2008, 374:479-484. 10.1016/j.bbrc.2008.07.042, 2997485, 18639520.
39. Sharma B, Iozzo RV. Transcriptional silencing of perlecan gene expression by interferon-gamma. J Biol Chem 1998, 273:4642-4646. 10.1074/jbc.273.8.4642, 9468523.
40. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000, 11:247-261. 10.1089/10430340050015996, 10680839.
41. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993, 11:571-611. 10.1146/annurev.iy.11.040193.003035, 8476573.
42. Zhang F, Lu W, Dong Z. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res 2002, 8:2942-2951.
43. Nielsen LL. NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model. Oncol Rep 2000, 7:151-155.
44. Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K, Fisher PB. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 2005, 65:9056-9063. 10.1158/0008-5472.CAN-05-1261, 16204080.
45. Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA. Functional T cells in athymic nude mice. Proc Natl Acad Sci U S A 1984, 81:886-888. 10.1073/pnas.81.3.886, 344943, 6608104.
46. Seliger B, Ruiz-Cabello F, Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 2008, 101:249-276.
47. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 2008, 226:41-56. 10.1111/j.1600-065X.2008.00707.x, 2630590, 19161415.
48. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570. 10.1126/science.1203486, 21436444.